Sarms & GLP1's
About this video
Gillett critiques cosmetic micro-use of GLP-1 medicines, using a media article to argue that small aesthetic goals in otherwise healthy people can carry disproportionate risks he discusses, including gastroparesis, gallbladder problems and longer-term muscle and bone loss. He then reviews early combination research pairing GLP-1 or amylin-based drugs with the SARM enobosarm to preserve muscle during weight loss, largely in older or sarcopenic patients and in cancer-related contexts. He notes concerns he raises about liver signals and virilization in some women, mocks anecdotal social-media reports presented as trial data, and rejects requests for sourcing outside medical care.
Key takeaways
- Aesthetic-only GLP-1 use changes the risk-benefit balance, Gillett argues
- Muscle preservation during weight loss is the rationale he describes for SARM combination trials
- Candidate selection matters: age, sarcopenia and hormone history shape suitability
- Anecdotal online cycle reports are not a substitute for published trial data
- Preserving bone and muscle matters more than scale weight alone
Episode details: published May 2, 2025 · 2.2K views · 35:50 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.
← Previous: What Size Needle Do I Need For A TRT Injection? · Next: We Answer Your Most Asked Questions | Ft. David Demesquita →
All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)
